Leading the Way in Life Science Technologies

GEN Exclusives

More »
Readers Comments Back to Item »

Paring, Sharing, and Snaring: Big Pharma's Latest R&D

1 Readers' Comments

Posted by: Jinjing LI

03/31/2011

<font face="Times New Roman"><span lang="EN-US">Crystal Pharmatech Co.,Ltd researchers held an incredibly successful two-day training program on polymorphism and solid state characterization</span><span style="mso-fareast-font-family: ??; mso-fareast-language: ZH-CN;" lang="EN-US"> </span><span lang="EN-US">at Suzhou Industrial Park, China March 24<sup>th</sup> and 25<sup>th</sup>.<span style="mso-spacerun: yes;">  </span>The training program was attended by over 130 researchers representing more than 7</span><span style="mso-fareast-font-family: ??; mso-fareast-language: ZH-CN;" lang="EN-US">0</span><span lang="EN-US"> China based pharmaceutical companies.<span style="mso-spacerun: yes;">  </span>Attendees included senior scientists and managers from global Pharm R&D centers in China including GSK, Novartis, Roche as well as other leading China-based companies including Huahai, Hengrui, and Donyangguang.<span style="mso-spacerun: yes;">  </span></span></font>

  • Click here to Login or to Register for free.

    You will be taken back to your selected item after Login/Registration.

Be sure to take the GEN Poll

Drug Price Hikes

Novum Pharma recently raised the price of an acne cream by over 3,900% in less than a year-and-a-half and Mylan increased price of EpiPen from $100 to $608 . Do you think pharmaceutical companies need to be subjected to price controls?

More »